DK3227311T3 - Indsættelige, variable fragmenter af antistoffer og modificerede A1- A2-domæner af NKG2D-ligander - Google Patents
Indsættelige, variable fragmenter af antistoffer og modificerede A1- A2-domæner af NKG2D-ligander Download PDFInfo
- Publication number
- DK3227311T3 DK3227311T3 DK15864650.5T DK15864650T DK3227311T3 DK 3227311 T3 DK3227311 T3 DK 3227311T3 DK 15864650 T DK15864650 T DK 15864650T DK 3227311 T3 DK3227311 T3 DK 3227311T3
- Authority
- DK
- Denmark
- Prior art keywords
- insertable
- domains
- antibodies
- modified
- variable fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088456P | 2014-12-05 | 2014-12-05 | |
PCT/US2015/064051 WO2016090278A2 (en) | 2014-12-05 | 2015-12-04 | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3227311T3 true DK3227311T3 (da) | 2022-03-07 |
Family
ID=56092677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15864650.5T DK3227311T3 (da) | 2014-12-05 | 2015-12-04 | Indsættelige, variable fragmenter af antistoffer og modificerede A1- A2-domæner af NKG2D-ligander |
Country Status (15)
Country | Link |
---|---|
US (2) | US11453713B2 (da) |
EP (3) | EP4043474A1 (da) |
JP (5) | JP2017537617A (da) |
AU (2) | AU2015357578B2 (da) |
CA (2) | CA2963274C (da) |
DK (1) | DK3227311T3 (da) |
ES (1) | ES2907467T3 (da) |
HR (1) | HRP20220531T1 (da) |
HU (1) | HUE058851T2 (da) |
LT (1) | LT3227311T (da) |
PL (1) | PL3227311T3 (da) |
PT (1) | PT3227311T (da) |
RS (1) | RS63149B1 (da) |
SI (1) | SI3227311T1 (da) |
WO (1) | WO2016090278A2 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10259858B2 (en) | 2015-08-04 | 2019-04-16 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors |
EP3475300A2 (en) * | 2016-06-24 | 2019-05-01 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
CN107964041B (zh) * | 2016-10-20 | 2023-08-01 | 中国科学院广州生物医药与健康研究院 | 高稳定性和高亲和力的dmic及其制法 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
CL2017003503A1 (es) | 2017-12-29 | 2018-06-01 | Univ Chile | Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a). |
BR112020016190A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpos direcionando o receptor nkg2d |
EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
MX2021005242A (es) * | 2018-11-05 | 2021-06-08 | Xyphos Biosciences Inc | Receptores nkg2d no naturales que no señalizan directamente las células a las que se unen. |
CA3130582A1 (en) * | 2019-02-18 | 2020-08-27 | Courier Therapeutics, Inc. | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class i-like protein (omcp) and tumor-specific binding partner |
EP4114860A1 (en) | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
JP2024512324A (ja) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
CA2315251A1 (en) | 1997-12-17 | 1999-06-24 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
JP2009514537A (ja) | 2005-11-03 | 2009-04-09 | ジェネンテック・インコーポレーテッド | 治療的抗her2抗体融合ポリペプチド |
CA2675024A1 (en) * | 2007-01-10 | 2008-07-17 | University Of Saskatchewan | Stabilization of cyclic peptide structures |
WO2012091756A1 (en) | 2010-12-30 | 2012-07-05 | Avidbiotics Corp. | Non-natural mic proteins |
US8796420B2 (en) * | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
RU2444570C1 (ru) | 2010-06-23 | 2012-03-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи" Министерства здравоохранения и социального развития Российской Федерации | Способ получения рекомбинантной вакцины |
EP2658867B1 (en) * | 2010-12-30 | 2018-02-28 | Avidbiotics Corp. | Non-natural mic proteins |
TWI408370B (zh) | 2011-05-19 | 2013-09-11 | Univ Chang Gung | 胰臟癌之血清生物檢測標誌及其應用 |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
WO2013117647A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
US11117969B2 (en) * | 2014-12-05 | 2021-09-14 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands |
US10259858B2 (en) * | 2015-08-04 | 2019-04-16 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors |
KR102523682B1 (ko) * | 2016-05-02 | 2023-04-19 | 에프. 호프만-라 로슈 아게 | 콘톨스바디 - 단쇄 표적 결합제 |
-
2015
- 2015-12-04 HR HRP20220531TT patent/HRP20220531T1/hr unknown
- 2015-12-04 US US14/959,745 patent/US11453713B2/en active Active
- 2015-12-04 EP EP21214432.3A patent/EP4043474A1/en active Pending
- 2015-12-04 EP EP22168795.7A patent/EP4079747A1/en active Pending
- 2015-12-04 PL PL15864650T patent/PL3227311T3/pl unknown
- 2015-12-04 CA CA2963274A patent/CA2963274C/en active Active
- 2015-12-04 PT PT158646505T patent/PT3227311T/pt unknown
- 2015-12-04 RS RS20220389A patent/RS63149B1/sr unknown
- 2015-12-04 DK DK15864650.5T patent/DK3227311T3/da active
- 2015-12-04 JP JP2017526866A patent/JP2017537617A/ja active Pending
- 2015-12-04 ES ES15864650T patent/ES2907467T3/es active Active
- 2015-12-04 EP EP15864650.5A patent/EP3227311B1/en active Active
- 2015-12-04 LT LTEPPCT/US2015/064051T patent/LT3227311T/lt unknown
- 2015-12-04 WO PCT/US2015/064051 patent/WO2016090278A2/en active Application Filing
- 2015-12-04 CA CA3204990A patent/CA3204990A1/en active Pending
- 2015-12-04 AU AU2015357578A patent/AU2015357578B2/en active Active
- 2015-12-04 HU HUE15864650A patent/HUE058851T2/hu unknown
- 2015-12-04 SI SI201531804T patent/SI3227311T1/sl unknown
-
2018
- 2018-08-31 AU AU2018223040A patent/AU2018223040B2/en active Active
-
2020
- 2020-03-30 JP JP2020061428A patent/JP7457558B2/ja active Active
- 2020-03-30 JP JP2020060639A patent/JP7132967B2/ja active Active
- 2020-03-30 JP JP2020061413A patent/JP7083862B2/ja active Active
-
2022
- 2022-03-31 JP JP2022060245A patent/JP2022093353A/ja active Pending
- 2022-09-13 US US17/931,596 patent/US20230002475A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3227311A4 (en) | 2018-08-01 |
PT3227311T (pt) | 2022-02-23 |
US11453713B2 (en) | 2022-09-27 |
EP4043474A1 (en) | 2022-08-17 |
EP3227311A2 (en) | 2017-10-11 |
US20160159882A1 (en) | 2016-06-09 |
AU2018223040A1 (en) | 2018-09-20 |
JP7457558B2 (ja) | 2024-03-28 |
CA2963274A1 (en) | 2016-06-09 |
US20230002475A1 (en) | 2023-01-05 |
WO2016090278A2 (en) | 2016-06-09 |
JP2022093353A (ja) | 2022-06-23 |
ES2907467T3 (es) | 2022-04-25 |
PL3227311T3 (pl) | 2022-05-16 |
JP7083862B2 (ja) | 2022-06-13 |
CA2963274C (en) | 2024-01-30 |
EP3227311B1 (en) | 2022-02-02 |
AU2018223040B2 (en) | 2020-04-30 |
AU2015357578B2 (en) | 2018-11-08 |
LT3227311T (lt) | 2022-02-25 |
JP2020114238A (ja) | 2020-07-30 |
JP2017537617A (ja) | 2017-12-21 |
JP7132967B2 (ja) | 2022-09-07 |
CA3204990A1 (en) | 2016-06-09 |
RS63149B1 (sr) | 2022-05-31 |
EP4079747A1 (en) | 2022-10-26 |
JP2020114854A (ja) | 2020-07-30 |
HUE058851T2 (hu) | 2022-09-28 |
HRP20220531T1 (hr) | 2022-06-10 |
AU2015357578A1 (en) | 2017-04-13 |
SI3227311T1 (sl) | 2022-04-29 |
JP2020114239A (ja) | 2020-07-30 |
WO2016090278A3 (en) | 2016-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3227311T3 (da) | Indsættelige, variable fragmenter af antistoffer og modificerede A1- A2-domæner af NKG2D-ligander | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
DK3350220T3 (da) | Anti-pro/latente-myostatin-antistoffer og anvendelser deraf | |
DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
DK3274370T3 (da) | Anti-ceacam6-antistoffer og anvendelser deraf | |
DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
DK3143042T3 (da) | Forbedrede variable immunoglobulindomæner | |
DK3313882T3 (da) | Anti-VISTA antistoffer og fragmenter | |
DK3182999T3 (da) | Anti-lag3-antistoffer og antigenbindingsfragmenter | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
DK3107938T3 (da) | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf | |
DK3221346T3 (da) | Antistoffer omfattende modificerede konstante områder af tungkæden | |
DK3149042T3 (da) | PD-L1-antistoffer og anvendelser deraf | |
DK3126394T3 (da) | Anti-OX40-antistoffer og fremgangsmåder til anvendelse | |
DK3148579T3 (da) | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf | |
DK3250610T3 (da) | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf | |
DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
DK3491025T3 (da) | Fcrn-antistoffer og anvendelsesmetoder heraf |